Suboptimal Exposure to Anti-TB Drugs in a TBM/HIV+ Population Is Not Related to Antiretroviral Therapy

Clinical Pharmacology and Therapeutics

Volumn 103, Issue 3, 2018, Pages 449-457

  Torok M E ^a   Aljayyoussi, G ^b   Waterhouse, D ^b   Chau, T T H ^c   Mai, N T H ^c   Phu, N H ^c   Hien, T T ^c   Hope, W ^d   Farrar, J J ^c   Ward, S A ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; METFORMIN; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; VIRUS RNA; ZIDOVUDINE; TUBERCULOSTATIC AGENT;

ABSORPTION LAG TIME; ADULT; ANTIBIOTIC THERAPY; ANTIRETROVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL OUTCOME; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MORTALITY; NEUROTOXICITY; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TUBERCULOUS MENINGITIS; VIET NAM; VOLUME OF DISTRIBUTION; AGED; COMPLICATION; DRUG INTERACTION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MALE; METABOLISM; MIDDLE AGED; MIXED INFECTION; SURVIVAL ANALYSIS; TOXICITY AND INTOXICATION; TREATMENT FAILURE;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; COINFECTION; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; SURVIVAL ANALYSIS; TREATMENT FAILURE; TUBERCULOSIS, MENINGEAL;

EID: 85029478469     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.646     Document Type: Article

References (38)

1. Rieder, H.L., Snider, D.E, Jr. & Cauthen, G.M. Extrapulmonary tuberculosis in the United States. Am. Rev. Respir. Dis. 141, 347–351 (1990).
2. WHO. Global tuberculosis report 2016. Geneva, Switzerland, 2016.
3. Thwaites, G.E. et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N. Engl. J. Med. 351, 1741–1751 (2004).
4. Rock, R.B., Olin, M., Baker, C.A., Molitor, T.W. & Peterson, P.K. Central nervous system tuberculosis: pathogenesis and clinical aspects. Clin. Microbiol. Rev. 21, 243–261 (2008).
5. Corbett, E.L. et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163, 1009–1021 (2003).
6. Thwaites, G.E. et al. The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with Tuberculous meningitis. J. Infect. Dis. 192, 2134–2141 (2005).
7. Lawn, S.D., Myer, L., Bekker, L.G. & Wood, R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. Aids 21, 335–341 (2007).
8. Abdool Karim, S.S. et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N. Engl. J. Med. 362, 697–706 (2010).
9. Bhatt, N.B. et al. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. Antimicrob. Agents Chemother. 58, 3182–3190 (2014).
10. Chideya, S. et al. isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin. Infect. Dis. 48, 1685–1694 (2009).
11. Perlman, D.C. et al. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin. Infect. Dis. 41, 1638–1647 (2005).
12. Asprodini, E.K., Zifa, E., Papageorgiou, I. & Benakis, A. Determination of N-acetylation phenotyping in a Greek population using caffeine as a metabolic probe. Eur. J. Drug Metab. Pharmacokinet. 23, 501–506 (1998).
13. D'Oliveira, J.J. Cerebrospinal fluid concentrations of rifampin in meningeal tuberculosis. Am. Rev. Respir. Dis. 106, 432–437 (1972).
14. Jonsson, S. et al. Population pharmacokinetics of ethambutol in South African tuberculosis patients. Antimicrob. Agents Chemother. 55, 4230–4237 (2011).
15. Israili, Z.H., Rogers, C.M. & el-Attar, H. Pharmacokinetics of antituberculosis drugs in patients. J. Clin. Pharmacol. 27, 78–83 (1987).
16. Lee, C.S., Gambertoglio, J.G., Brater, D.C. & Benet, L.Z. Kinetics of oral ethambutol in the normal subject. Clin. Pharmacol. Ther. 22(5 Pt 1), 615–621 (1977).
17. McIlleron, H., Wash, P., Burger, A., Norman, J., Folb, P.I. & Smith, P. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob. Agents Chemother. 50, 1170–1177 (2006).
18. Babalik, A. et al. Pharmacokinetics and serum concentrations of antimycobacterial drugs in adult Turkish patients. Int. J. Tubercul. Lung Dis. 17, 1442–1447 (2013).
19. Tostmann, A. et al. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients. Antimicrob. Agents Chemother. 57, 3208–3213 (2013).
20. Kergueris, M.F., Bourin, M. & Larousse, C. Pharmacokinetics of isoniazid: influence of age. Eur. J. Clin. Pharmacol. 30, 335–340 (1986).
21. Burhan, E. et al. isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob. Agents Chemother. 57, 3614–3619 (2013).
22. De-jian, S., Xu-li, D. & Ji-hui, D. The history of the elimination of lymphatic filariasis in China. Infect. Dis. Poverty 2, 1 (2013).
23. Lacroix, C. et al. Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects. Eur. J. Clin. Pharmacol. 36, 395–400 (1989).
24. Loos, U. et al. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin. Wochen. 63, 1205–1211 (1985).
25. Milan Segovia, R.C. et al. Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis. J. Clin. Pharm. Ther. 38, 56–61 (2013).
26. Ruslami, R. et al. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob. Agents Chemother. 51, 2546–2551 (2007).
27. Blanc, F.X. et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N. Engl. J. Med. 365, 1471–1481 (2011).
28. Torok, M.E. et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)—associated tuberculous meningitis. Clin. Infect. Dis. 52, 1374–1383 (2011).
29. Reynolds, J. & Heysell, S.K. Understanding pharmacokinetics to improve tuberculosis treatment outcome. Expert Opin. Drug Metab. Toxicol. 10, 813–823 (2014).
30. Rastogi, N., Labrousse, V. & Goh, K.S. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr. Microbiol. 33, 167–175 (1996).
31. Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis 90, 279–292 (2010).
32. Pouplin, T. et al. Naive-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis. BMC Infect. Dis. 16, 144 (2016).
33. Saleri, N. et al. Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso. J. Antimicrob. Chemother. 67, 469–472 (2012).
34. Patel, K.B., Belmonte, R. & Crowe, H.M. Drug malabsorption and resistant tuberculosis in HIV-infected patients. N. Engl. J. Med. 332, 336–337 (1995).
35. Heemskerk, A.D. et al. Intensified antituberculosis therapy in adults with tuberculous meningitis. N. Engl. J. Med. 374, 124–134 (2016).
36. Schaberg, T., Rebhan, K. & Lode, H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur. Respir. J. 9, 2026–2030 (1996).
37. Guidances (Drugs). In: Administration) USFaD, editor; 2015.
38. Neely, M.N., van Guilder, M.G., Yamada, W.M., Schumitzky, A. & Jelliffe, R.W. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther. Drug Monit. 34, 467–476 (2012).